Moderna, Inc. (MRNA) $55.81
Moderna is currently flashing a rare ‘screaming oversold’ signal with an RSI of 19.9, yet the stock remains trapped in a brutal technical downtrend just 48 hours before earnings.
52-wk High $85.6
📌 Investment Snapshot
- Price of $55.81 sits 34.8% below the 52-week high despite a 22.1% three-month gain.
- Latest Q1 2026 revenue of $0.39B and EPS of -$3.40 highlight ongoing cash burn.
- RSI at 19.9 indicates extreme selling pressure and a potential short-term relief rally.
- Consensus target of $49.37 suggests the stock is still 11% overvalued by analysts.
⏳ WAIT
Moderna is facing a high-stakes earnings report on July 31st while technicals scream exhaustion. The stock is currently sandwiched between a declining SMA50 and a rising SMA200, creating a volatility pinch.
| 📍 Entry Zone | $51.41 or below | 🛑 Stop-Loss | $44.00 |
| 📋 Adjust If | Q2 revenue exceeds $0.5B or RSV vaccine adoption surprises to the upside. | ||
The Investment Case — Why Now?
Over the last 90 days, Moderna’s narrative shifted from a speculative recovery play to a defensive battleground. While the stock rallied 22% in the spring, the recent 17% monthly slide reflects growing anxiety over the commercial ramp-up of its non-COVID pipeline. Institutional heavyweights like FMR and Blackrock maintain massive positions, yet the price action suggests they are not currently defending the $60 level.
The primary risk remains the staggering $-0.7B free cash flow burn recorded in the latest quarter. With a short interest of 16.1%, any earnings miss could trigger a liquidity hunt toward the $47 Anchored VWAP. Conversely, a positive surprise could ignite a massive short squeeze given the 5.2 days to cover.
Does Moderna’s current $22B valuation accurately reflect its post-pandemic pipeline, or is the market still pricing in a ‘COVID-era’ premium that no longer exists?
🤔 Does Moderna’s current $22B valuation accurately reflect its post-pandemic pipeline, or is the market still pricing in a ‘COVID-era’ premium that no longer exists?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| CEO | Stéphane Bancel |
| Employees | 5,900+ |
Open chart on TradingView →
📈 Price Action & Technicals
Dead Cross
Outside VA
Sell-side Sweep at $67.74 on 2026-07-10
The technical backdrop for MRNA is currently a study in extremes. While the stock is trading below its SMA50 ($57.92), it remains above the critical SMA200 ($44.43), suggesting the long-term trend hasn’t fully broken. This ‘no-man’s land’ positioning makes the upcoming earnings a binary event for the chart.
RSI at 19.9 is the lowest reading in over a year, which typically precedes a mean-reversion bounce. However, the ADX at 41.0 coupled with a dominant -DI of 43.5 confirms a powerful bearish trend that often ignores oversold signals. Traders should look for a divergence in the RSI before betting on a reversal.
The Volume Profile Point of Control (POC) sits at $51.41, acting as a magnet for price action. We are currently trading just above the Value Area High ($55.21), meaning a failure to hold current levels likely leads to a fast drop toward that $51.41 support. This zone represents the most significant institutional ‘fair value’ over the past year.
Recent liquidity sweeps at $67.74 suggest that ‘smart money’ exited positions during the July rally. The three unfilled bearish Fair Value Gaps (FVGs) between $57 and $61 now act as heavy overhead resistance. Any rally will likely stall at $57.46 unless accompanied by massive volume.
Historically, when MRNA enters the earnings window with such a depressed RSI, volatility expands by 1.5x the 20-day average. The Bollinger Bands are currently wide, with the lower band at $48.88 providing a secondary floor. Expect a violent move toward either the $47 VWAP or the $60 resistance gap.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| MRNA | Moderna, Inc. | N/A |
| BNTX | BioNTech SE | 24.1x |
| PFE | Pfizer Inc. | 12.8x |
| VRTX | Vertex Pharma | 28.5x |
| SPY | S&P 500 Avg | 21.4x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $0.39B | -$3.40 | -15% |
| Q4 2025 | $0.68B | -$2.11 | -22% |
| Q3 2025 | $1.00B | -$0.51 | -10% |
| Q2 2025 | $0.14B | -$2.13 | -40% |
Moderna reported a free cash flow of $-0.7B in the latest quarter, reflecting heavy R&D investment in its oncology and rare disease pipeline.
Revenue remains highly seasonal and volatile as the company transitions away from its COVID-19 dependence. The market is laser-focused on the commercial trajectory of the newly launched RSV vaccine and the progress of the Merck-partnered cancer vaccine.
🚀 Growth Drivers — What Moves the Stock
- RSV Vaccine Launch 🟢 Upside Surprise — The mRESVIA launch is the first major test of Moderna’s commercial infrastructure outside of COVID-19.
- Oncology Pipeline (mRNA-4157) 🟢 Upside Surprise — Ongoing Phase 3 trials with Merck for melanoma could validate the platform for broader cancer applications.
- Cost Efficiency Program 🟡 Priced In — Management’s ability to trim the $1.1B quarterly OpEx is critical for extending the cash runway.
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| FMR, LLC | 45,672 |
| Blackrock Inc. | 29,635 |
| Vanguard Capital | 22,872 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| HOGE STEPHEN | President | 2026-07-15 | Sale | 53,336 |
| MOCK JAMES M | CFO | 2026-07-02 | Sale | 1,452 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 16.1% | 5.2 |
⚠ Key Risk Factors
~$4B impact
Valuation compression
~$1B revenue risk
🤔 With insiders like Stephen Hoge consistently selling shares in July, should you be buying what the executives are offloading?
🎯 Guidance & Wall Street View
Management has previously signaled 2026 as a ‘transition year’ with a return to organic sales growth expected by 2027.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $79.00 | $49.37 | $25.00 | 19 | Hold |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Goldman Sachs | Neutral | $52.00 | 2026-07-21 | Maintained |
| B of A Securities | Underperform | $35.00 | 2026-07-07 | Maintained |
The analyst community is skeptical, with the mean target sitting 11.5% below current prices, suggesting further downside is the base case.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Oversold RSI (19.9) triggers a massive short squeeze on any positive earnings news.
- RSV vaccine adoption exceeds conservative analyst estimates.
📊 Base Case
Moderna continues to burn cash while slowly building its non-COVID portfolio, keeping the stock range-bound between $45 and $60.
🐻 Bear Case
- Earnings miss leads to a break of the SMA200 at $44.43.
- Continued insider selling signals lack of confidence in near-term catalysts.
🎯 Investor Action Plan — By Profile
The RSI is attractive, but the ADX confirms a strong downtrend. Wait for a reclaim of $57.50 on high volume to fill the first bearish gap before entering.
With earnings in 48 hours, the risk-reward is skewed to the downside. Let the volatility settle and look for an entry near the $51.41 Volume Profile POC.
If you own MRNA for the 2030 mRNA platform thesis, stay the course. However, do not add to the position until the cash burn shows signs of peaking.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: When is Moderna's next earnings date?
Moderna is scheduled to report its Q2 2026 earnings on July 31, 2026.
Q: Is Moderna stock oversold?
Yes, with an RSI of 19.9, MRNA is technically in extreme oversold territory, though this does not guarantee an immediate bounce.
Q: What is the price target for MRNA?
The consensus mean price target is $49.37, which is approximately 11.5% lower than the current market price.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to verify if this analysis still holds?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Biotech stocks carry high volatility and clinical trial risk.
All active positions and their real-time performance are tracked on our Investment Log.
#MRNA #Moderna #Biotech #StockMarket #Investing #mRNA #WallStreet #Nasdaq